AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia

Clinical trial NCT04147949 · UNKNOWN

Trial details

NCT number: NCT04147949
Sponsor: VistaGen Therapeutics, Inc.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Parkinson Disease Dyskinesia, Medication-Induced L-Dopa Causing Adverse Effects in Therapeutic Use

Start date: 2022-08-01
Primary completion: 2023-12-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.